Share |

Verisante Technology, Inc. Recognizes May as National Skin Cancer Awareness Month

May 2, 2014 at 1:00 pm

VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer detection technology, recognizes May as skin cancer awareness month and reminds the public to wear sunscreen and get screened for skin cancer.

Skin cancer is the most common form of cancer in the world, with the World Health Organization reporting one in every three cancers diagnosed is a skin cancer.  The incidence of both non-melanoma and melanoma skin cancers have been increasing at a rate of approximately 3% per year. One in seven Canadians will develop skin cancer during their lifetime while one in five Americans will, and over 3.5 million cases of skin cancer are diagnosed annually in the USA.  

The good news is that early detection through regular skin cancer screenings and the daily use of sunscreen can be highly effective in preventing the spread of the disease.

Verisante Aura™, a device for the detection of skin cancer, is now being used by doctors in Canada to assist them in the assessment of skin cancer.  Skin cancer patients are urged to ask their doctor about the benefits of an AuraScan™.

“Verisante has placed two additional Aura’s™ in Canada in the past two months, said Thomas Braun, President and CEO.  “The Company’s direct sales team, which was established in February, continues to make excellent progress in assessing additional locations across the country where Aura™ will be most useful to doctors and patients.”

In honour of Melanoma May, a medical clinic in downtown Toronto is offering a chance to win one of five non-invasive skin cancer assessments using Aura™.  Patients may enter to win through the clinic’s website

Medical Professionals interested in learning more about using Aura™ in their practice can contact the Company directly at 

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. Core™ has not yet been approved for sale. 

Verisante Aura™ was awarded Popular Science Magazine’s “Best of What’s New Award” for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. 

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. 

Company Contact:

Thomas Braun, President & CEO
Verisante Technology, Inc.
Telephone: (604) 605-0507

Forward Looking Statements 

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

  Back to top